Mitokines and the mitochondria-as-endocrine-organ model
The reframing of mitochondria as endocrine signalling organs, rather than purely bioenergetic ones, is one of the more significant conceptual shifts in ageing biology over the past two decades. The term 'mitokine' has emerged to describe peptides and other signalling molecules produced by mitochondria, or produced elsewhere in response to mitochondrial stress, that act on distant tissues to coordinate a systemic response — a communication role directly analogous to classical endocrine hormones, but originating from an organelle rather than a dedicated gland.
Humanin, discovered by Hashimoto et al. (2001, PNAS) in a screen for factors protecting neurons from Alzheimer's-disease-related toxicity, is the founding member of this class and remains the best-characterised. It is encoded within the mitochondrial 16S rRNA gene, translated as a short open reading frame product, and released into circulation where it acts on the CNTFR-WSX1-gp130 receptor complex discussed elsewhere in this catalogue's mitochondrial-peptide coverage. Its association with longevity in centenarian-offspring cohorts (Yen et al., 2014) is among the clearer human epidemiological signals in this space.
MOTS-c, discovered by the same Cong Lin / Pinchas Cohen research lineage in 2015 (Kim et al., Cell Metab), is encoded in the 12S rRNA gene and represents a second, mechanistically distinct mitokine. Where Humanin acts predominantly through a cell-surface receptor complex, MOTS-c's best-characterised action involves direct nuclear translocation and chromatin binding under metabolic stress, in addition to its AMPK-activating systemic signalling. This dual mode — local nuclear action and distal endocrine-like signalling — illustrates that 'mitokine' is a functional category rather than a single mechanism.
The Small Humanin-Like Peptides (SHLP1 through SHLP6), described by Cobb et al. (2016, Aging), extend the mitochondrial 16S rRNA-derived peptide family beyond Humanin itself. Early characterisation work suggests differing, partially overlapping activity profiles across metabolic and cell-survival endpoints, with SHLP2 and SHLP3 receiving the most attention to date for effects on insulin sensitivity and mitochondrial respiration in cell-culture models. This sub-family remains considerably less characterised than Humanin or MOTS-c, and is included here for completeness of the mitokine picture rather than as an established research-catalogue candidate in its own right.
GDF15 (growth differentiation factor 15) is worth noting for context, though it is not a mitochondrially-encoded peptide in the same sense as Humanin or MOTS-c — it is a nuclear-genome-encoded stress-response cytokine whose expression is nonetheless strongly induced by mitochondrial dysfunction, and it circulates at markedly elevated levels in patients with primary mitochondrial disease, as described by Fujita et al. (2015, PLOS ONE) among others. GDF15's inclusion in the broader mitokine conversation illustrates that mitochondrial stress signalling extends beyond the small set of peptides literally encoded within the mitochondrial genome itself.
SS-31, by contrast, is not a mitokine by this definition at all — it is a synthetic, exogenously administered peptide designed to stabilise cardiolipin rather than a naturally occurring signalling molecule produced by the body in response to mitochondrial state. It is grouped with Humanin and MOTS-c in this catalogue's broader mitochondrial-peptide category on the basis of shared target organelle, not shared mechanism, and this distinction is worth preserving precisely when discussing the mitokine model specifically.
The integrated picture this research area is building toward is a model in which mitochondrial health status in one tissue is communicated systemically via this peptide and cytokine repertoire, allowing distant tissues to adjust their own metabolic and stress-response programmes in a coordinated fashion. This is mechanistically elegant and consistent with the broader shift in ageing biology toward viewing organ systems as interconnected signalling networks rather than independently ageing units, but the model remains substantially built on animal and cell-culture data, with human evidence concentrated mainly in observational biomarker associations (Humanin and centenarian longevity, GDF15 and mitochondrial disease severity) rather than interventional trials.
The practical research question following from this model is whether combined mitokine-panel measurement — Humanin, MOTS-c, relevant SHLPs and GDF15 together — offers better predictive value for biological ageing trajectory than any single marker alone, given that each appears to capture a partially distinct aspect of mitochondrial stress signalling. No published work has yet validated such a combined panel specifically, and this represents a clear, currently unfilled research opportunity building directly on the individual-peptide evidence already summarised across this catalogue.